Home > Insider Trading > Filing (0001502213-10-000002)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885590	Valeant Pharmaceuticals International Inc.	VRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1502213	Roswell Robert Chai-Onn	7150 Mississauga Road Mississauga A6 L5N 8M5	Evp, Gc & Corp. Sec.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares, No Par Value	Disposition	2010-11-09	35,607	$25.95	18,511	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The common shares were sold pursuant to a 10b5-1 Selling Plan adopted by the Reporting Person on September 14, 2010.
Represents long-term performance units (the "Performance Units") received upon conversion of the reporting person's Valeant Pharmaceuticals International ("old Valeant") Performance Units that were held prior to the merger between the issuer (formerly known as Biovail Corporation) and old Valeant (the "Merger"), in accordance with the terms of the Merger agreement between the issuer and, amongst others, old Valeant, less common shares withheld to satisfy the tax withholding obligations due upon vesting of RSUs.
The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.92 to $26.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, in each case upon request, full information regarding the number of shares sold at each separate price.
Represents restricted share units received upon conversion of the reporting person's old Valeant restricted stock units that were held prior to the Merger, which were previously reported in Table I.